Background: Data on indirect effects of dementia treatment on caregiver burden obtained from naturalistic studies are still lacking. We explored differences between patients with oral and transdermal application of acetylcholine esterase inhibitors regarding caregiver’s time burden and psychopathology. Methods: A cross-sectional naturalistic cohort study of 403 patients in outpatient care with three treatment groups (none, oral, and transdermal) was conducted. Assessments included a standardized clinical burden questionnaire and a standardized caregiver interview. Results: Any treatment was associated with lower burden in most measures. Transdermal treatment was superior regarding (1) administration time (p Conclusions: Benefits associated ...
Carina Wattmo, Elisabeth Paulsson, Lennart Minthon, Elisabet LondosClinical Memory Research Unit, De...
Background and objectives: The quality of life (QoL) of caregivers of Alzheimer’s Disease (AD) patie...
Background Quality of Life (QoL) is a key outcome in dementia. Aim To compare care recipients' (CR) ...
Background/Aims: According to experimental data, a transdermal application is preferred by caregiver...
According to experimental data, a transdermal application is preferred by caregivers of Alzheimer's ...
Introduction. Research into medications for Alzheimer's disease (AD) is primarily conducted in drug...
Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 She...
AIM: The aim of the study was to determine whether the clinical benefits of galantamine for patients...
Aim: The aim of the study was to determine whether the clinical benefits of galantamine for patients...
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dement...
Background: Dementia is a neurodegenerative disease whose prevalence is rising, and the need for ass...
Abstract Purpose:The purpose of this article is to compare and analyze acetylcholinesterase inhibito...
Background and aims: To collect opinions, perceptions, and expectations on the therapeutic benefits ...
Background: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the ...
Introduction: Rivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first ch...
Carina Wattmo, Elisabeth Paulsson, Lennart Minthon, Elisabet LondosClinical Memory Research Unit, De...
Background and objectives: The quality of life (QoL) of caregivers of Alzheimer’s Disease (AD) patie...
Background Quality of Life (QoL) is a key outcome in dementia. Aim To compare care recipients' (CR) ...
Background/Aims: According to experimental data, a transdermal application is preferred by caregiver...
According to experimental data, a transdermal application is preferred by caregivers of Alzheimer's ...
Introduction. Research into medications for Alzheimer's disease (AD) is primarily conducted in drug...
Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 She...
AIM: The aim of the study was to determine whether the clinical benefits of galantamine for patients...
Aim: The aim of the study was to determine whether the clinical benefits of galantamine for patients...
Secundino López-Pousa,1 Francisco Javier Arranz21Unit for Assessment of Memory and Dement...
Background: Dementia is a neurodegenerative disease whose prevalence is rising, and the need for ass...
Abstract Purpose:The purpose of this article is to compare and analyze acetylcholinesterase inhibito...
Background and aims: To collect opinions, perceptions, and expectations on the therapeutic benefits ...
Background: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the ...
Introduction: Rivastigmine, a treatment for mild to moderate Alzheimer disease (AD), is the first ch...
Carina Wattmo, Elisabeth Paulsson, Lennart Minthon, Elisabet LondosClinical Memory Research Unit, De...
Background and objectives: The quality of life (QoL) of caregivers of Alzheimer’s Disease (AD) patie...
Background Quality of Life (QoL) is a key outcome in dementia. Aim To compare care recipients' (CR) ...